University of Minnesota seeks participants for skin disease studyApril 5, 2019University of Minnesota (UMN) College of Veterinary Medicine is looking for candidates to enroll in an allergic skin disease study. The clinical trial will assess the safety and efficacy of a topical gel for dogs with atopic dermatitis (AD), which is a skin condition that causes severe itching and is hard to manage. According to the researchers, many of the current treatments produce unwanted side effects or they do not fully treat the symptoms. The study will last 14 days and will require the participants to visit UMN on day zero, seven, and 14. The dogs' owners will be required to use a topical gel on areas of their pets' skin and keep a medication diary throughout the duration. During the visits, Sheila Torres, DVM, MS, PhD, DACVD, will examine and assess the participants. Blood samples will be taken every visit and urine samples on day zero and 14. There is no cost, and at the end of the study dog owners will be eligible for to a $200 debit card. To participate dogs must: • have a short hair coat; • have red and inflamed skin, especially on their belly and/or paws; • have a …
SPONSORED CONTENTHow can you help new pet owners keep their new dogs protected?See why new dog owners and their pets can benefit from simple triple protection in one monthly chew. + See the Difference
Clinical trial shows possible longer life for dogs with osteosarcomaNovember 1, 2018Fifteen dogs diagnosed with osteosarcoma survived a median time of 415 days after completing canine osteosarcoma immunotherapy, according to a clinical trial by ELIAS Animal Health.
Alzheimer's drug used in cognitive dysfunction syndrome clinical trialSeptember 5, 2018Ropesalazine, a drug candidate for Alzheimer's disease (AD), has shown efficacy in a pilot clinical trial conducted for dogs with cognitive dysfunction syndrome (CDS), according to the drug's manufacturer, South Korea-based GNT Pharma. There currently is no cure for CDS, a progressive neurodegenerative disorder of senior dogs characterized by altered interaction with family, disorientation, sleep/wake cycle changes, increased house soiling, and activity change. It is accompanied by nerve cell death, amyloid plaques, and neurofibrillary tangles similar to AD, leading GNT Pharma scientists to design the pilot study to investigate whether Ropesalazine would alleviate signs of CDS, as well. "The companion dogs failed to recognize their owners before the treatment," said Jae Bong Moon, DVM, head of Irion Animal Hospital in Seoul, who led the study. "It was so amazing to see the dogs that wagged their tails for their owners and cuddled up to them within eight weeks of Ropesalazine treatment. [It] appeared to cure CDS." The study was conducted on six companion dogs age 10 or older who revealed severe cognitive dysfunction according to canine cognitive dysfunction and canine dementia rating scales. Within eight weeks following daily oral administration of Ropesalazine, all six dogs returned …
OSU enrolling dogs with mammary cancer for clinical trialAugust 29, 2018Oregon State University's Lois Bates Acheson Veterinary Teaching Hospital is now enrolling dogs with mammary cancer in a new clinical trial. Dog owners considering standard tumor removal surgery may be able to choose a new surgical procedure involving an intravenous injection of a cancer cell-illuminating nanoparticle compound that highlights exactly which tissue needs to be removed. After the mammary tumor is removed, the surrounding tissue is irradiated with an infrared laser that causes the nanoparticle compound to heat up, killing any remaining cancer cells. The compound, developed by researchers in the Oregon State University College of Pharmacy, has been found to effectively cure cancer in mice. The new procedure eventually may be most beneficial for treating tumors in challenging anatomic areas, such as the brain and spine, according to Milan Milovancev, DVM, DACVS-SA, an OSU associate professor of small animal surgery participating in the study. The Oregon State University Carlson College of Veterinary Medicine is a member of a national consortium of veterinary oncology centers, managed by the National Institutes of Health, with a focus on translational veterinary medicine. Owners who believe their pets may be good trial candidates can ask their veterinarian …
Auburn Oncology Service launches melanoma drug clinical trialApril 5, 2018The Oncology Service at Auburn University's College of Veterinary Medicine is using the help of man's best friend in launching a clinical trial to test a new melanoma treatment drug. "This study is designed to test a new drug that may be useful in treating melanoma, which most commonly occurs in the mouth in dogs," said Bruce Smith, VMD, Ph.D., a professor in the Department of Pathobiology and director of the Auburn University Research Initiative in Cancer, or AURIC. "The drug, called MMX, is a peptide, which is a chain of amino acids, the basic building blocks of all proteins," Dr. Smith said. "This study seeks to measure the effect of this drug on these tumors. We are currently taking patients to participate in the clinical trial." Dog owners who are interested in enrolling their pets into this clinical trial must do so through the Oncology Service at the college's Wilford and Kate Bailey Small Animal Teaching Hospital. The treatment, as well as surgery to remove any tumor left at the end of the trial, will be provided at no cost to the owner. The trial initially is about a five-week …
ASU awarded $6.4M grant to test preventive canine cancer vaccineJanuary 8, 2018Arizona State University (ASU) professor Stephen Albert Johnson, Ph.D., has received a $6.4 million grant from the Open Philanthropy Project to support a clinical trial of a vaccine to prevent canine cancer. The trial will involve approximately 800 middle-aged, healthy pet dogs and will test the effects of a multivalent frameshift peptide (FSP) vaccine developed at ASU that has shown promise in mouse studies. Scientists think the vaccine has potential for human use, too. "Our goal has always been that if this is possible, we should at least try it," said Johnston, director of the Biodesign Center for Innovations in Medicine and CEO of Calviri Inc., a cancer vaccine company. "Open Philanthropy was the only organization that responded to support our high-risk project, the biggest cancer intervention trial in dogs ever." Johnston and his team developed the new FSP vaccine over the past 10 years. The vaccine, already tested for efficacy in mice, is shown to be safe in dogs, according to Johnston's research. Cancer is the leading cause of death in pet dogs and their cancers are very similar to their human counterparts. Some breeds have a very high cancer rate, as much as 40 percent. The canine …
Dental product earns veterinary oral health council sealSeptember 28, 2017Two clinical studies show that SwedencareUSA's ProDen PlaqueOff Dental Bites for dogs significantly reduce the formation of plaque and tartar. As a result, the bites earned the Veterinary Oral Health Council (VOHC) health claim seal "helps control plaque and tartar." Jerzy Gawor, DVM, Ph.D., president of Federation of European Companion Animal Veterinary Associations and president elect of the European Veterinary Dental College, performed the studies. "VOHC acceptance is an important indicator in the efficacy of pet dental health products," said Martin Shimko, president of SwedencareUSA in Poulsbo, Wash. "Pets love them, and now … there is science behind the product." Study methods Two groups of dogs, one group with small dogs, and one with small and medium size dogs, participated in the studies. Between two subgroups, one received ProDen PlaqueOff Dental Bites and one received a placebo without the bites' active ingredient, Ascophyllum nodosum. All dogs were examined and had their teeth cleaned prior to the study. Study results After 30 days, researchers measured for plaque and tartar. Groups receiving ProDen PlaqueOff Dental Bites had significantly less plaque and …
AKC Canine Health Foundation funds clinical trial to study cannabidiol in treating drug-resistant epilepsy in dogsSeptember 14, 2017By Veterinary Practice News Editors The AKC Canine Health Foundation (CHF), which has funded more than $2 million for canine epilepsy research, launched an initiative in 2017 to further understand the most common neurological disorder that affects pure- and mixed-breed dogs. Improved treatments are urgently needed, especially for dogs with drug-resistant epilepsy or where side effects of currently available drugs are not tolerated, according to the organization. To that, the CHF has announced the beginning a major clinical trial to study the use of cannabidiol to treat drug resistant epilepsy in dogs. Stephanie McGrath, MS, DVM, DACVIM (Neurology), at Colorado State University's College of Veterinary Medicine and Biomedical Sciences, will lead "Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy." According to Dr. McGrath, up to 30 percent of dogs receiving standard anti-epileptic therapy remain uncontrolled for their seizures, and the side effects of the antiepileptic drugs are often unacceptable. CBD, a nonpsychotropic component of the Cannabis sativa plant, has been shown to have anticonvulsant properties; this randomized, double-blinded, placebo-controlled, crossover clinical trial study will be utilized to prove its effectiveness, she stated. "The timeliness and importance of research into the role of cannabis in …
UC Davis seeks dogs with pulmonic stenosisSeptember 13, 2016A new clinical trial by the University of California, Davis School of Veterinary Medicine is focusing on dogs with pulmonic stenosis, one of the most common congenital heart defects in dogs.
